Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261693 | 0.89 | KDM4E (0.52) | TSHRALDH1A1HMGCRCHRM1TBXA2R | |
| SCHEMBL1409381 | 0.88 | — | — | |
| SCHEMBL11324877 | 0.85 | — | — | |
| SCHEMBL13343045 | 0.83 | TSHR (0.38) | TSHRALDH1A1TP53HMGCRCHRM1 | |
| SCHEMBL1409491 | 0.83 | TSHR (0.43) | TSHRALDH1A1TP53HMGCRCHRM1 | |
| SCHEMBL11318440 | 0.83 | — | — | |
| SCHEMBL2526094 | 0.83 | TSHR (0.40) | TSHRALDH1A1TP53KDM4E | |
| SCHEMBL27941651 | 0.81 | FFAR1 (0.39) | TSHRALDH1A1TP53TDP1KDM4E | |
| SCHEMBL12055332 | 0.81 | DGKA (0.38) | TSHRALDH1A1TP53ADRA1A | |
| SCHEMBL212208 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119619-A | Anti-aging PE pipe and preparation method thereof | 甘肃海纳塑业有限公司 | 2024-12-13 | — | — | CN | claimed |
| EP-1149836-B1 | Polynalbuphine derivatives | HU OLIVER YOA PU (TW) | 2003-02-26 | — | — | EP | claimed |
| EP-1149836-A1 | Polynalbuphine derivatives | Hu, Oliver Yoa-Pu (TW) | 2001-10-31 | — | — | EP | claimed |
| CN-119119619-A | Anti-aging PE pipe and preparation method thereof | 甘肃海纳塑业有限公司 | 2024-12-13 | — | — | CN | disclosed |
| EP-3796900-A1 | TRITERPENE AMINE DERIVATIVES | DFH Therapeutics (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20170096446-A1 | Extended Triterpene Derivatives | MYREXIS, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-9505800-B2 | Extended triterpene derivatives | MYREXIS, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20120046291-A1 | Extended Triterpene Derivatives | MYREXIS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2008057420-A2 | EXTENDED TRITERPENE DERIVATIVES | PANACOS PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
| EP-1401810-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| EP-1149836-B1 | Polynalbuphine derivatives | HU OLIVER YOA PU (TW) | 2003-02-26 | — | — | EP | disclosed |
| WO-2003004468-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
| EP-1149836-A1 | Polynalbuphine derivatives | Hu, Oliver Yoa-Pu (TW) | 2001-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096446-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | TSHR 4604/4885ALDH1A1 4419/4885TP53 3061/4885 |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | TSHR 3931/4885ALDH1A1 827/4885TP53 1510/4885 |
| US-20120046291-A1 | Extended Triterpene Derivatives | BET1, PGGT1B, TMPO | TSHR 4604/4885ALDH1A1 4419/4885TP53 3061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.